ID   PDE9A_HUMAN             Reviewed;         593 AA.
AC   O76083; B2RBI5; B4DFI5; D3DSJ8; D3DSJ9; O75490; O75491; O95225;
AC   Q53Y40; Q5QD39; Q86SF7; Q86SI6; Q86SJ3; Q86WN3; Q86WN4; Q86WN5;
AC   Q86WN6; Q86WN7; Q86WN8; Q86WN9; Q86WP0;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   22-JUL-2015, entry version 146.
DE   RecName: Full=High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A {ECO:0000305};
DE            EC=3.1.4.35 {ECO:0000269|PubMed:18757755, ECO:0000269|PubMed:21483814, ECO:0000269|PubMed:9624146};
GN   Name=PDE9A {ECO:0000312|HGNC:HGNC:8795};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PDE9A1), FUNCTION, CATALYTIC
RP   ACTIVITY, ENZYME REGULATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Brain, Prostate, and Testis;
RX   PubMed=9624146; DOI=10.1074/jbc.273.25.15559;
RA   Fisher D.A., Smith J.F., Pillar J.S., St Denis S.H., Cheng J.B.;
RT   "Isolation and characterization of PDE9A, a novel human cGMP-specific
RT   phosphodiesterase.";
RL   J. Biol. Chem. 273:15559-15564(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS PDE9A1; PDE9A2;
RP   PDE9A3 AND PDE9A4).
RC   TISSUE=Fetal brain;
RX   PubMed=9856478; DOI=10.1007/s004390050838;
RA   Guipponi M., Scott H.S., Kudoh J., Kawasaki K., Shibuya K.,
RA   Shintani A., Asakawa S., Chen H., Lalioti M.D., Rossier C.,
RA   Minoshima S., Shimizu N., Antonarakis S.E.;
RT   "Identification and characterization of a novel cyclic nucleotide
RT   phosphodiesterase gene (PDE9A) that maps to 21q22.3: alternative
RT   splicing of mRNA transcripts, genomic structure and sequence.";
RL   Hum. Genet. 103:386-392(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS PDE9A5; PDE9A6; PDE9A7; PDE9A9;
RP   PDE9A10; PDE9A11; PDE9A12; PDE9A13; PDE9A16; PDE9A17 AND PDE9A18), AND
RP   TISSUE SPECIFICITY.
RX   PubMed=12565835; DOI=10.1016/S0006-291X(03)00021-4;
RA   Rentero C., Monfort A., Puigdomenech P.;
RT   "Identification and distribution of different mRNA variants produced
RT   by differential splicing in the human phosphodiesterase 9A gene.";
RL   Biochem. Biophys. Res. Commun. 301:686-692(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PDE9A6).
RC   TISSUE=Brain, Small intestine, and Spleen;
RX   PubMed=14527714; DOI=10.1016/S0378-1119(03)00733-9;
RA   Wang P., Wu P., Egan R.W., Billah M.M.;
RT   "Identification and characterization of a new human type 9 cGMP-
RT   specific phosphodiesterase splice variant (PDE9A5). Differential
RT   tissue distribution and subcellular localization of PDE9A variants.";
RL   Gene 314:15-27(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PDE9A21), AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=17090334; DOI=10.1186/1471-2199-7-39;
RA   Rentero C., Puigdomenech P.;
RT   "Specific use of start codons and cellular localization of splice
RT   variants of human phosphodiesterase 9A gene.";
RL   BMC Mol. Biol. 7:39-39(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS PDE9A1 AND PDE9A3).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM PDE9A2).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10830953; DOI=10.1038/35012518;
RA   Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T.,
RA   Park H.-S., Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y.,
RA   Soeda E., Ohki M., Takagi T., Sakaki Y., Taudien S., Blechschmidt K.,
RA   Polley A., Menzel U., Delabar J., Kumpf K., Lehmann R., Patterson D.,
RA   Reichwald K., Rump A., Schillhabel M., Schudy A., Zimmermann W.,
RA   Rosenthal A., Kudoh J., Shibuya K., Kawasaki K., Asakawa S.,
RA   Shintani A., Sasaki T., Nagamine K., Mitsuyama S., Antonarakis S.E.,
RA   Minoshima S., Shimizu N., Nordsiek G., Hornischer K., Brandt P.,
RA   Scharfe M., Schoen O., Desario A., Reichelt J., Kauer G., Bloecker H.,
RA   Ramser J., Beck A., Klages S., Hennig S., Riesselmann L., Dagand E.,
RA   Wehrmeyer S., Borzym K., Gardiner K., Nizetic D., Francis F.,
RA   Lehrach H., Reinhardt R., Yaspo M.-L.;
RT   "The DNA sequence of human chromosome 21.";
RL   Nature 405:311-319(2000).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM PDE9A2).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   ENZYME REGULATION.
RX   PubMed=16150925; DOI=10.1124/mol.105.017608;
RA   Wunder F., Tersteegen A., Rebmann A., Erb C., Fahrig T., Hendrix M.;
RT   "Characterization of the first potent and selective PDE9 inhibitor
RT   using a cGMP reporter cell line.";
RL   Mol. Pharmacol. 68:1775-1781(2005).
RN   [12]
RP   TISSUE SPECIFICITY.
RX   PubMed=22328573; DOI=10.1124/jpet.111.191353;
RA   Kleiman R.J., Chapin D.S., Christoffersen C., Freeman J.,
RA   Fonseca K.R., Geoghegan K.F., Grimwood S., Guanowsky V., Hajos M.,
RA   Harms J.F., Helal C.J., Hoffmann W.E., Kocan G.P., Majchrzak M.J.,
RA   McGinnis D., McLean S., Menniti F.S., Nelson F., Roof R.,
RA   Schmidt A.W., Seymour P.A., Stephenson D.T., Tingley F.D.,
RA   Vanase-Frawley M., Verhoest P.R., Schmidt C.J.;
RT   "Phosphodiesterase 9A regulates central cGMP and modulates responses
RT   to cholinergic and monoaminergic perturbation in vivo.";
RL   J. Pharmacol. Exp. Ther. 341:396-409(2012).
RN   [13]
RP   REVIEW.
RX   PubMed=24746902; DOI=10.1016/j.lfs.2014.04.007;
RA   Singh N., Patra S.;
RT   "Phosphodiesterase 9: insights from protein structure and role in
RT   therapeutics.";
RL   Life Sci. 106:1-11(2014).
RN   [14]
RP   FUNCTION, ENZYME REGULATION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY,
RP   AND INDUCTION.
RX   PubMed=25799991; DOI=10.1038/nature14332;
RA   Lee D.I., Zhu G., Sasaki T., Cho G.S., Hamdani N., Holewinski R.,
RA   Jo S.H., Danner T., Zhang M., Rainer P.P., Bedja D., Kirk J.A.,
RA   Ranek M.J., Dostmann W.R., Kwon C., Margulies K.B., Van Eyk J.E.,
RA   Paulus W.J., Takimoto E., Kass D.A.;
RT   "Phosphodiesterase 9A controls nitric-oxide-independent cGMP and
RT   hypertrophic heart disease.";
RL   Nature 519:472-476(2015).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.23 ANGSTROMS) OF 241-566 IN COMPLEX WITH THE
RP   INHIBITOR IBMX, AND SUBUNIT.
RX   PubMed=15210993; DOI=10.1073/pnas.0401120101;
RA   Huai Q., Wang H., Zhang W., Colman R.W., Robinson H., Ke H.;
RT   "Crystal structure of phosphodiesterase 9 shows orientation variation
RT   of inhibitor 3-isobutyl-1-methylxanthine binding.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:9624-9629(2004).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 242-566 IN COMPLEX WITH
RP   MAGNESIUM; ZINC; GMP AND CGMP, ACTIVE SITE, FUNCTION, CATALYTIC
RP   ACTIVITY, COFACTOR, AND MUTAGENESIS OF HIS-312 AND HIS-356.
RX   PubMed=18757755; DOI=10.1073/pnas.0708850105;
RA   Liu S., Mansour M.N., Dillman K.S., Perez J.R., Danley D.E.,
RA   Aeed P.A., Simons S.P., Lemotte P.K., Menniti F.S.;
RT   "Structural basis for the catalytic mechanism of human
RT   phosphodiesterase 9.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:13309-13314(2008).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 241-566 IN COMPLEX WITH
RP   ZINC.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Crystal structure of the human phosphodiesterase 9a catalytic
RT   domain.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [18] {ECO:0000244|PDB:3JSI, ECO:0000244|PDB:3JSW}
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 242-566 IN COMPLEX WITH
RP   MAGNESIUM; ZINC AND PF-4181366 INHIBITOR, ENZYME REGULATION, AND
RP   COFACTOR.
RX   PubMed=19919087; DOI=10.1021/jm9015334;
RA   Verhoest P.R., Proulx-Lafrance C., Corman M., Chenard L., Helal C.J.,
RA   Hou X., Kleiman R., Liu S., Marr E., Menniti F.S., Schmidt C.J.,
RA   Vanase-Frawley M., Schmidt A.W., Williams R.D., Nelson F.R.,
RA   Fonseca K.R., Liras S.;
RT   "Identification of a brain penetrant PDE9A inhibitor utilizing
RT   prospective design and chemical enablement as a rapid lead
RT   optimization strategy.";
RL   J. Med. Chem. 52:7946-7949(2009).
RN   [19] {ECO:0000244|PDB:3K3E, ECO:0000244|PDB:3K3H}
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 241-566 IN COMPLEX WITH
RP   MAGNESIUM; ZINC AND BAY-73-6691 INHIBITOR, ENZYME REGULATION,
RP   COFACTOR, AND MUTAGENESIS OF MET-425; ILE-463; LEU-480; TYR-484;
RP   PHE-501; GLN-513 AND PHE-516.
RX   PubMed=20121115; DOI=10.1021/jm901519f;
RA   Wang H., Luo X., Ye M., Hou J., Robinson H., Ke H.;
RT   "Insight into binding of phosphodiesterase-9A selective inhibitors by
RT   crystal structures and mutagenesis.";
RL   J. Med. Chem. 53:1726-1731(2010).
RN   [20] {ECO:0000244|PDB:3QI3, ECO:0000244|PDB:3QI4}
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF MUTANT GLU-513 IN COMPLEX
RP   WITH MAGNESIUM; ZINC AND (S)-BAY-73-6691 INHIBITOR, ENZYME REGULATION,
RP   COFACTOR, FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND MUTAGENESIS OF GLU-466 AND GLN-513.
RX   PubMed=21483814; DOI=10.1371/journal.pone.0018092;
RA   Hou J., Xu J., Liu M., Zhao R., Luo H.B., Ke H.;
RT   "Structural asymmetry of phosphodiesterase-9, potential protonation of
RT   a glutamic acid, and role of the invariant glutamine.";
RL   PLoS ONE 6:E18092-E18092(2011).
RN   [21] {ECO:0000244|PDB:4GH6}
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 241-566 IN COMPLEX WITH
RP   MAGNESIUM; ZINC AND INHIBITOR 28, COFACTOR, AND ENZYME REGULATION.
RX   PubMed=22985069; DOI=10.1021/jm301189c;
RA   Meng F., Hou J., Shao Y.X., Wu P.Y., Huang M., Zhu X., Cai Y., Li Z.,
RA   Xu J., Liu P., Luo H.B., Wan Y., Ke H.;
RT   "Structure-based discovery of highly selective phosphodiesterase-9A
RT   inhibitors and implications for inhibitor design.";
RL   J. Med. Chem. 55:8549-8558(2012).
RN   [22] {ECO:0000244|PDB:4E90, ECO:0000244|PDB:4G2J, ECO:0000244|PDB:4G2L}
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 242-566 IN COMPLEX WITH
RP   MAGNESIUM; ZINC AND INHIBITOR, COFACTOR, AND ENZYME REGULATION.
RX   PubMed=23025719; DOI=10.1021/jm3009635;
RA   Claffey M.M., Helal C.J., Verhoest P.R., Kang Z., Fors K.S., Jung S.,
RA   Zhong J., Bundesmann M.W., Hou X., Lui S., Kleiman R.J.,
RA   Vanase-Frawley M., Schmidt A.W., Menniti F., Schmidt C.J.,
RA   Hoffman W.E., Hajos M., McDowell L., O'Connor R.E.,
RA   Macdougall-Murphy M., Fonseca K.R., Becker S.L., Nelson F.R.,
RA   Liras S.;
RT   "Application of structure-based drug design and parallel chemistry to
RT   identify selective, brain penetrant, in vivo active phosphodiesterase
RT   9A inhibitors.";
RL   J. Med. Chem. 55:9055-9068(2012).
CC   -!- FUNCTION: Specifically hydrolyzes the second messenger cGMP, which
CC       is a key regulator of many important physiological processes.
CC       Highly specific: compared to other members of the cyclic
CC       nucleotide phosphodiesterase family, has the highest affinity and
CC       selectivity for cGMP (PubMed:9624146, PubMed:18757755,
CC       PubMed:21483814). Specifically regulates natriuretic-peptide-
CC       dependent cGMP signaling in heart, acting as a regulator of
CC       cardiac hypertrophy in myocytes and muscle. Does not regulate
CC       nitric oxide-dependent cGMP in heart (PubMed:25799991). Additional
CC       experiments are required to confirm whether its ability to
CC       hydrolyze natriuretic-peptide-dependent cGMP is specific to heart
CC       or is a general feature of the protein (Probable). In brain,
CC       involved in cognitive function, such as learning and long-term
CC       memory (By similarity). {ECO:0000250|UniProtKB:Q8QZV1,
CC       ECO:0000269|PubMed:18757755, ECO:0000269|PubMed:21483814,
CC       ECO:0000269|PubMed:25799991, ECO:0000269|PubMed:9624146,
CC       ECO:0000305}.
CC   -!- CATALYTIC ACTIVITY: Guanosine 3',5'-cyclic phosphate + H(2)O =
CC       guanosine 5'-phosphate. {ECO:0000269|PubMed:18757755,
CC       ECO:0000269|PubMed:21483814, ECO:0000269|PubMed:9624146}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:19919087,
CC         ECO:0000269|PubMed:20121115, ECO:0000269|PubMed:21483814,
CC         ECO:0000269|PubMed:22985069, ECO:0000269|PubMed:23025719,
CC         ECO:0000305|PubMed:18757755};
CC       Note=Binds 1 Zn(2+) ion per subunit. Binds 2 divalent metal
CC       cations per subunit: site 1 preferentially binds zinc, while site
CC       2 has a preference for magnesium. Tightly binds zinc.
CC       {ECO:0000269|PubMed:19919087, ECO:0000269|PubMed:20121115,
CC       ECO:0000269|PubMed:21483814, ECO:0000269|PubMed:22985069,
CC       ECO:0000269|PubMed:23025719, ECO:0000305|PubMed:18757755};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:19919087,
CC         ECO:0000269|PubMed:20121115, ECO:0000269|PubMed:21483814,
CC         ECO:0000269|PubMed:22985069, ECO:0000269|PubMed:23025719,
CC         ECO:0000305|PubMed:18757755};
CC       Note=Binds 1 Mg(2+) ions per subunit. Binds 2 divalent metal
CC       cations per subunit: site 1 preferentially binds zinc, while site
CC       2 has a preference for magnesium. Binds magnesium less tightly
CC       than zinc. {ECO:0000269|PubMed:19919087,
CC       ECO:0000269|PubMed:20121115, ECO:0000269|PubMed:21483814,
CC       ECO:0000269|PubMed:22985069, ECO:0000269|PubMed:23025719,
CC       ECO:0000305|PubMed:18757755};
CC   -!- ENZYME REGULATION: Inhibited by zaprinast; inhibitor is however
CC       not specific to PDE9A (PubMed:9624146). Specifically inhibited by
CC       BAY-73-6691 (1-(2-chlorophenyl)-6-((2R)-3,3,3- trifluoro-2-
CC       methylpropyl)-1,5-dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one)
CC       (PubMed:16150925). BAY-73-9961 has two enantiomers, (R) and (S),
CC       due to the presence of a chiral center, and both forms vary in
CC       their pattern of interaction (PubMed:20121115, PubMed:21483814).
CC       Specifically inhibited by PF-4181366 (4H-Pyrazolo[3,4-d]pyrimidin-
CC       4-one, 1- cyclopentyl-1,5-dihydro-6-[(3S,4S)-4-methyl- 1-(6-
CC       quinoxalinylmethyl)-3-pyrrolidinyl]-one) (PubMed:19919087).
CC       Specifically inhibited by PF-4449613 ((R)-6-(1-(3-phenoxyazetidin-
CC       1-yl)ethyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-
CC       d]pyrimidin- 4(5H)-one) (PubMed:25799991). Specifically inhibited
CC       by inhibitor 28 (2-((1-(2-Chlorophenyl)-4-hydroxy-1Hpyrazolo[ 3,4-
CC       d]pyrimidin-6-yl)amino)-N-(4- methoxyphenyl)propanamide):
CC       inhibitor forms a hydrogen bond with Tyr-484 and Gln-513
CC       (PubMed:22985069). Specifically inhibited by 1-Cyclopentyl-6-
CC       [(1r)-1-(3-phenoxyazetidin- 1-Yl)ethyl]-1,5-dihydro-4h-
CC       pyrazolo[3,4-D] pyrimidin-4-one: inhibitor forms a hydrogen bond
CC       with Tyr-484 and Gln-513 (PubMed:23025719).
CC       {ECO:0000269|PubMed:16150925, ECO:0000269|PubMed:19919087,
CC       ECO:0000269|PubMed:20121115, ECO:0000269|PubMed:21483814,
CC       ECO:0000269|PubMed:22985069, ECO:0000269|PubMed:23025719,
CC       ECO:0000269|PubMed:25799991, ECO:0000269|PubMed:9624146,
CC       ECO:0000303|PubMed:24746902}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.113 uM for cGMP {ECO:0000269|PubMed:21483814};
CC         KM=501 uM for cAMP {ECO:0000269|PubMed:21483814};
CC         Vmax=0.285 umol/min/mg enzyme with cGMP as substrate
CC         {ECO:0000269|PubMed:21483814};
CC         Vmax=3.7 umol/min/mg enzyme with cAMP as substrate
CC         {ECO:0000269|PubMed:21483814};
CC         Note=kcat is 0.18 sec(-1) for cGMP. kcat is 2.37 sec(-1) for
CC         cAMP. {ECO:0000269|PubMed:21483814};
CC   -!- PATHWAY: Purine metabolism; 3',5'-cyclic GMP degradation; GMP from
CC       3',5'-cyclic GMP: step 1/1.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:15210993,
CC       ECO:0000269|PubMed:21483814}.
CC   -!- INTERACTION:
CC       O95817:BAG3; NbExp=3; IntAct=EBI-742764, EBI-747185;
CC       A2RU00:C9orf106; NbExp=3; IntAct=EBI-742764, EBI-10173129;
CC       P49759:CLK1; NbExp=3; IntAct=EBI-742764, EBI-473775;
CC       Q49AN0:CRY2; NbExp=3; IntAct=EBI-742764, EBI-2212355;
CC       Q9H8Y8:GORASP2; NbExp=3; IntAct=EBI-742764, EBI-739467;
CC       P60410:KRTAP10-8; NbExp=3; IntAct=EBI-742764, EBI-10171774;
CC       Q9BYR5:KRTAP4-2; NbExp=3; IntAct=EBI-742764, EBI-10172511;
CC       Q9BYQ4:KRTAP9-2; NbExp=3; IntAct=EBI-742764, EBI-1044640;
CC       Q14657:LAGE3; NbExp=3; IntAct=EBI-742764, EBI-1052105;
CC       P25791:LMO2; NbExp=3; IntAct=EBI-742764, EBI-739696;
CC       Q9BRA0:NAA38; NbExp=3; IntAct=EBI-742764, EBI-9106509;
CC       Q7Z3S9:NOTCH2NL; NbExp=3; IntAct=EBI-742764, EBI-945833;
CC       Q96FC7-2:PHYHIPL; NbExp=3; IntAct=EBI-742764, EBI-10285660;
CC       P49888:SULT1E1; NbExp=3; IntAct=EBI-742764, EBI-712512;
CC       Q13049:TRIM32; NbExp=6; IntAct=EBI-742764, EBI-742790;
CC       Q9BRU9:UTP23; NbExp=3; IntAct=EBI-742764, EBI-5457544;
CC       Q9Y260:ZFAB; NbExp=3; IntAct=EBI-742764, EBI-750052;
CC   -!- SUBCELLULAR LOCATION: Isoform PDE9A1: Cell projection, ruffle
CC       membrane {ECO:0000269|PubMed:17090334}. Cytoplasm, perinuclear
CC       region {ECO:0000269|PubMed:17090334}. Golgi apparatus
CC       {ECO:0000269|PubMed:17090334}. Endoplasmic reticulum
CC       {ECO:0000269|PubMed:17090334}. Cell membrane, sarcolemma
CC       {ECO:0000269|PubMed:25799991}.
CC   -!- SUBCELLULAR LOCATION: Isoform PDE9A2: Cell projection, ruffle
CC       membrane {ECO:0000269|PubMed:17090334}. Cytoplasm, perinuclear
CC       region {ECO:0000269|PubMed:17090334}.
CC   -!- SUBCELLULAR LOCATION: Isoform PDE9A3: Cytoplasm
CC       {ECO:0000269|PubMed:17090334}. Endoplasmic reticulum
CC       {ECO:0000269|PubMed:17090334}.
CC   -!- SUBCELLULAR LOCATION: Isoform PDE9A17: Cytoplasm
CC       {ECO:0000269|PubMed:17090334}. Endoplasmic reticulum
CC       {ECO:0000269|PubMed:17090334}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=16;
CC       Name=PDE9A1;
CC         IsoId=O76083-1; Sequence=Displayed;
CC       Name=PDE9A2;
CC         IsoId=O76083-2; Sequence=VSP_004599;
CC       Name=PDE9A3;
CC         IsoId=O76083-3; Sequence=VSP_004598, VSP_004599;
CC       Name=PDE9A4;
CC         IsoId=O76083-4; Sequence=VSP_004600;
CC       Name=PDE9A5;
CC         IsoId=O76083-5; Sequence=VSP_017309;
CC       Name=PDE9A6; Synonyms=PDE9A5;
CC         IsoId=O76083-6; Sequence=VSP_017305, VSP_004599;
CC       Name=PDE9A7; Synonyms=PDE9A8, PDE9A14, PDE9A19, PDE9A20;
CC         IsoId=O76083-7; Sequence=VSP_017303;
CC       Name=PDE9A9;
CC         IsoId=O76083-8; Sequence=VSP_017307, VSP_004599;
CC       Name=PDE9A10;
CC         IsoId=O76083-9; Sequence=VSP_017304, VSP_017310;
CC       Name=PDE9A11; Synonyms=PDE9A15;
CC         IsoId=O76083-10; Sequence=VSP_017302, VSP_017311;
CC       Name=PDE9A12;
CC         IsoId=O76083-11; Sequence=VSP_017305, VSP_017308;
CC       Name=PDE9A13;
CC         IsoId=O76083-12; Sequence=VSP_017306;
CC       Name=PDE9A16;
CC         IsoId=O76083-13; Sequence=VSP_004598;
CC       Name=PDE9A17;
CC         IsoId=O76083-14; Sequence=VSP_017305;
CC       Name=PDE9A18;
CC         IsoId=O76083-15; Sequence=VSP_017307;
CC       Name=PDE9A21;
CC         IsoId=O76083-16; Sequence=VSP_038647, VSP_004599;
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues examined (testis,
CC       brain, small intestine, skeletal muscle, heart, lung, thymus,
CC       spleen, placenta, kidney, liver, pancreas, ovary and prostate)
CC       except blood (PubMed:9624146). Highest levels in brain, heart,
CC       kidney, spleen, prostate and colon. Isoform PDE9A12 is found in
CC       prostate (PubMed:12565835). In brain, present in the cortex,
CC       cerebellum, and subiculum (at protein level) (PubMed:22328573). In
CC       heart, primarily localizes to myocytes (PubMed:25799991).
CC       {ECO:0000269|PubMed:12565835, ECO:0000269|PubMed:22328573,
CC       ECO:0000269|PubMed:25799991, ECO:0000269|PubMed:9624146}.
CC   -!- INDUCTION: Up-regulated in left ventricular hypertrophy from
CC       aortic stenosis and following heart failure with preserved
CC       ejection fraction (at protein level).
CC       {ECO:0000269|PubMed:25799991}.
CC   -!- MISCELLANEOUS: PDE9A is a potential target for treatment of
CC       diseases such as stress-induced heart disease or long-term memory
CC       defects. Specific inhibitors, such as BAY-73-6691 or PF-4449613
CC       are promising candidates for clinical tests.
CC       {ECO:0000303|PubMed:24746902, ECO:0000305|PubMed:25799991}.
CC   -!- SIMILARITY: Belongs to the cyclic nucleotide phosphodiesterase
CC       family. PDE9 subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF048837; AAC39778.1; -; mRNA.
DR   EMBL; AB017602; BAA88847.1; -; Genomic_DNA.
DR   EMBL; AF067223; AAC26723.1; -; mRNA.
DR   EMBL; AF067224; AAC26724.1; -; mRNA.
DR   EMBL; AF067225; AAC26725.1; -; mRNA.
DR   EMBL; AF067226; AAC26726.1; -; mRNA.
DR   EMBL; AY196299; AAO34685.1; -; mRNA.
DR   EMBL; AY196300; AAO34686.1; -; mRNA.
DR   EMBL; AY196301; AAO34687.1; -; mRNA.
DR   EMBL; AY196302; AAO34688.1; -; mRNA.
DR   EMBL; AY196303; AAO34689.1; -; mRNA.
DR   EMBL; AY196304; AAO34690.1; -; mRNA.
DR   EMBL; AY196305; AAO34691.1; -; mRNA.
DR   EMBL; AY196306; AAO34692.1; -; mRNA.
DR   EMBL; AY196307; AAO34693.1; -; mRNA.
DR   EMBL; AY196308; AAO34694.1; -; mRNA.
DR   EMBL; AY196309; AAO34695.1; -; mRNA.
DR   EMBL; AY196310; AAO34696.1; -; mRNA.
DR   EMBL; AY196311; AAO34697.1; -; mRNA.
DR   EMBL; AY196312; AAO34698.1; -; mRNA.
DR   EMBL; AY196313; AAO34699.1; -; mRNA.
DR   EMBL; AY196314; AAO34700.1; -; mRNA.
DR   EMBL; AY242121; AAO88210.1; -; mRNA.
DR   EMBL; AY701187; AAV84271.1; -; mRNA.
DR   EMBL; AK294112; BAG57446.1; -; mRNA.
DR   EMBL; AK314679; BAG37232.1; -; mRNA.
DR   EMBL; BT007016; AAP35662.1; -; mRNA.
DR   EMBL; AP001747; BAA95552.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09544.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09536.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09537.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09541.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09542.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09546.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09540.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09548.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09549.1; -; Genomic_DNA.
DR   EMBL; BC009047; AAH09047.1; -; mRNA.
DR   CCDS; CCDS13690.1; -. [O76083-1]
DR   CCDS; CCDS33567.1; -. [O76083-5]
DR   CCDS; CCDS33568.1; -. [O76083-2]
DR   CCDS; CCDS33569.1; -. [O76083-15]
DR   CCDS; CCDS33570.1; -. [O76083-12]
DR   CCDS; CCDS33571.1; -. [O76083-4]
DR   CCDS; CCDS42941.1; -. [O76083-8]
DR   CCDS; CCDS42942.1; -. [O76083-14]
DR   CCDS; CCDS42943.1; -. [O76083-6]
DR   CCDS; CCDS42944.1; -. [O76083-11]
DR   CCDS; CCDS42945.1; -. [O76083-13]
DR   CCDS; CCDS42946.1; -. [O76083-3]
DR   CCDS; CCDS42947.1; -. [O76083-9]
DR   RefSeq; NP_001001567.1; NM_001001567.1. [O76083-2]
DR   RefSeq; NP_001001568.1; NM_001001568.1. [O76083-3]
DR   RefSeq; NP_001001569.1; NM_001001569.1. [O76083-4]
DR   RefSeq; NP_001001570.1; NM_001001570.1. [O76083-5]
DR   RefSeq; NP_001001571.1; NM_001001571.1. [O76083-6]
DR   RefSeq; NP_001001572.1; NM_001001572.1. [O76083-7]
DR   RefSeq; NP_001001573.1; NM_001001573.1. [O76083-7]
DR   RefSeq; NP_001001574.1; NM_001001574.1. [O76083-8]
DR   RefSeq; NP_001001575.1; NM_001001575.1. [O76083-9]
DR   RefSeq; NP_001001576.1; NM_001001576.1. [O76083-10]
DR   RefSeq; NP_001001577.1; NM_001001577.1. [O76083-11]
DR   RefSeq; NP_001001578.1; NM_001001578.1. [O76083-12]
DR   RefSeq; NP_001001579.1; NM_001001579.1. [O76083-7]
DR   RefSeq; NP_001001580.1; NM_001001580.1. [O76083-10]
DR   RefSeq; NP_001001581.1; NM_001001581.1. [O76083-13]
DR   RefSeq; NP_001001582.1; NM_001001582.1. [O76083-14]
DR   RefSeq; NP_001001583.1; NM_001001583.1. [O76083-15]
DR   RefSeq; NP_001001584.1; NM_001001584.2. [O76083-7]
DR   RefSeq; NP_001001585.1; NM_001001585.1. [O76083-7]
DR   RefSeq; NP_002597.1; NM_002606.2. [O76083-1]
DR   RefSeq; XP_011527903.1; XM_011529601.1. [O76083-16]
DR   UniGene; Hs.473927; -.
DR   PDB; 2HD1; X-ray; 2.23 A; A/B=241-566.
DR   PDB; 2YY2; X-ray; 2.80 A; A/B=241-566.
DR   PDB; 3DY8; X-ray; 2.15 A; A/B=242-566.
DR   PDB; 3DYL; X-ray; 2.70 A; A/B=242-566.
DR   PDB; 3DYN; X-ray; 2.10 A; A/B=242-566.
DR   PDB; 3DYQ; X-ray; 2.50 A; A/B=242-566.
DR   PDB; 3DYS; X-ray; 2.30 A; A/B=242-566.
DR   PDB; 3JSI; X-ray; 2.72 A; A/B=242-566.
DR   PDB; 3JSW; X-ray; 2.30 A; A/B=242-566.
DR   PDB; 3K3E; X-ray; 2.70 A; A/B=241-566.
DR   PDB; 3K3H; X-ray; 2.50 A; A/B=241-566.
DR   PDB; 3N3Z; X-ray; 2.75 A; A/B=241-566.
DR   PDB; 3QI3; X-ray; 2.30 A; A/B=1-593.
DR   PDB; 3QI4; X-ray; 2.50 A; A/B=1-593.
DR   PDB; 4E90; X-ray; 2.50 A; A/B=242-566.
DR   PDB; 4G2J; X-ray; 2.40 A; A/B=242-566.
DR   PDB; 4G2L; X-ray; 3.00 A; A/B=242-566.
DR   PDB; 4GH6; X-ray; 2.70 A; A/B=241-566.
DR   PDBsum; 2HD1; -.
DR   PDBsum; 2YY2; -.
DR   PDBsum; 3DY8; -.
DR   PDBsum; 3DYL; -.
DR   PDBsum; 3DYN; -.
DR   PDBsum; 3DYQ; -.
DR   PDBsum; 3DYS; -.
DR   PDBsum; 3JSI; -.
DR   PDBsum; 3JSW; -.
DR   PDBsum; 3K3E; -.
DR   PDBsum; 3K3H; -.
DR   PDBsum; 3N3Z; -.
DR   PDBsum; 3QI3; -.
DR   PDBsum; 3QI4; -.
DR   PDBsum; 4E90; -.
DR   PDBsum; 4G2J; -.
DR   PDBsum; 4G2L; -.
DR   PDBsum; 4GH6; -.
DR   ProteinModelPortal; O76083; -.
DR   SMR; O76083; 245-566.
DR   BioGrid; 111178; 20.
DR   IntAct; O76083; 17.
DR   MINT; MINT-1444906; -.
DR   STRING; 9606.ENSP00000291539; -.
DR   BindingDB; O76083; -.
DR   ChEMBL; CHEMBL2363066; -.
DR   DrugBank; DB00201; Caffeine.
DR   GuidetoPHARMACOLOGY; 1309; -.
DR   PhosphoSite; O76083; -.
DR   BioMuta; PDE9A; -.
DR   PaxDb; O76083; -.
DR   PRIDE; O76083; -.
DR   DNASU; 5152; -.
DR   Ensembl; ENST00000291539; ENSP00000291539; ENSG00000160191.
DR   Ensembl; ENST00000328862; ENSP00000328699; ENSG00000160191. [O76083-15]
DR   Ensembl; ENST00000335440; ENSP00000335365; ENSG00000160191. [O76083-12]
DR   Ensembl; ENST00000335512; ENSP00000335242; ENSG00000160191. [O76083-2]
DR   Ensembl; ENST00000349112; ENSP00000344730; ENSG00000160191. [O76083-4]
DR   Ensembl; ENST00000380328; ENSP00000369685; ENSG00000160191. [O76083-5]
DR   Ensembl; ENST00000398224; ENSP00000381280; ENSG00000160191. [O76083-3]
DR   Ensembl; ENST00000398225; ENSP00000381281; ENSG00000160191. [O76083-14]
DR   Ensembl; ENST00000398227; ENSP00000381283; ENSG00000160191. [O76083-9]
DR   Ensembl; ENST00000398229; ENSP00000381285; ENSG00000160191. [O76083-11]
DR   Ensembl; ENST00000398232; ENSP00000381287; ENSG00000160191. [O76083-13]
DR   Ensembl; ENST00000398234; ENSP00000381289; ENSG00000160191. [O76083-6]
DR   Ensembl; ENST00000398236; ENSP00000381291; ENSG00000160191. [O76083-8]
DR   GeneID; 5152; -.
DR   KEGG; hsa:5152; -.
DR   UCSC; uc002zbm.3; human. [O76083-1]
DR   UCSC; uc002zbn.3; human. [O76083-3]
DR   UCSC; uc002zbo.3; human. [O76083-5]
DR   UCSC; uc002zbq.3; human. [O76083-12]
DR   UCSC; uc002zbt.3; human. [O76083-4]
DR   UCSC; uc002zbu.3; human. [O76083-11]
DR   UCSC; uc002zbv.3; human. [O76083-9]
DR   UCSC; uc002zbw.3; human. [O76083-10]
DR   UCSC; uc002zbx.3; human. [O76083-2]
DR   UCSC; uc002zbz.3; human. [O76083-16]
DR   UCSC; uc002zca.3; human. [O76083-14]
DR   UCSC; uc002zcb.3; human. [O76083-15]
DR   UCSC; uc002zcc.3; human. [O76083-6]
DR   UCSC; uc002zcd.3; human. [O76083-8]
DR   UCSC; uc002zce.3; human. [O76083-13]
DR   UCSC; uc010gpf.1; human. [O76083-7]
DR   CTD; 5152; -.
DR   GeneCards; GC21P044073; -.
DR   HGNC; HGNC:8795; PDE9A.
DR   HPA; HPA011380; -.
DR   MIM; 602973; gene.
DR   neXtProt; NX_O76083; -.
DR   PharmGKB; PA33143; -.
DR   eggNOG; NOG268427; -.
DR   GeneTree; ENSGT00760000118889; -.
DR   HOVERGEN; HBG053545; -.
DR   KO; K13761; -.
DR   OMA; PRAFKIN; -.
DR   OrthoDB; EOG7DFXC4; -.
DR   PhylomeDB; O76083; -.
DR   TreeFam; TF314638; -.
DR   BRENDA; 3.1.4.35; 2681.
DR   Reactome; REACT_23767; cGMP effects.
DR   UniPathway; UPA00763; UER00748.
DR   ChiTaRS; PDE9A; human.
DR   EvolutionaryTrace; O76083; -.
DR   GeneWiki; PDE9A; -.
DR   GenomeRNAi; 5152; -.
DR   NextBio; 19884; -.
DR   PRO; PR:O76083; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   Bgee; O76083; -.
DR   Genevisible; O76083; HS.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042383; C:sarcolemma; IDA:UniProtKB.
DR   GO; GO:0047555; F:3',5'-cyclic-GMP phosphodiesterase activity; IDA:UniProtKB.
DR   GO; GO:0004114; F:3',5'-cyclic-nucleotide phosphodiesterase activity; TAS:ProtInc.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0046069; P:cGMP catabolic process; IDA:UniProtKB.
DR   GO; GO:0046068; P:cGMP metabolic process; IDA:UniProtKB.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 1.10.1300.10; -; 1.
DR   InterPro; IPR003607; HD/PDEase_dom.
DR   InterPro; IPR023088; PDEase.
DR   InterPro; IPR002073; PDEase_catalytic_dom.
DR   InterPro; IPR023174; PDEase_CS.
DR   Pfam; PF00233; PDEase_I; 1.
DR   PRINTS; PR00387; PDIESTERASE1.
DR   SMART; SM00471; HDc; 1.
DR   PROSITE; PS00126; PDEASE_I; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Cell projection;
KW   cGMP; Complete proteome; Cytoplasm; Endoplasmic reticulum;
KW   Golgi apparatus; Hydrolase; Magnesium; Membrane; Metal-binding;
KW   Reference proteome; Zinc.
FT   CHAIN         1    593       High affinity cGMP-specific 3',5'-cyclic
FT                                phosphodiesterase 9A.
FT                                /FTId=PRO_0000198841.
FT   NP_BIND     312    316       cGMP. {ECO:0000269|PubMed:18757755}.
FT   NP_BIND     512    513       cGMP. {ECO:0000269|PubMed:18757755}.
FT   REGION      288    550       Catalytic. {ECO:0000250}.
FT   ACT_SITE    312    312       Proton donor.
FT                                {ECO:0000269|PubMed:18757755}.
FT   METAL       316    316       Zinc; via tele nitrogen.
FT                                {ECO:0000244|PDB:2HD1,
FT                                ECO:0000244|PDB:2YY2,
FT                                ECO:0000244|PDB:3DYN,
FT                                ECO:0000244|PDB:3JSI,
FT                                ECO:0000244|PDB:3JSW,
FT                                ECO:0000244|PDB:3K3E,
FT                                ECO:0000244|PDB:3K3H,
FT                                ECO:0000244|PDB:3N3Z,
FT                                ECO:0000244|PDB:4E90,
FT                                ECO:0000244|PDB:4G2J,
FT                                ECO:0000244|PDB:4G2L,
FT                                ECO:0000244|PDB:4GH6,
FT                                ECO:0000269|PubMed:18757755,
FT                                ECO:0000269|PubMed:19919087,
FT                                ECO:0000269|PubMed:20121115,
FT                                ECO:0000269|PubMed:21483814,
FT                                ECO:0000269|PubMed:22985069,
FT                                ECO:0000269|PubMed:23025719}.
FT   METAL       352    352       Zinc; via tele nitrogen.
FT                                {ECO:0000244|PDB:2HD1,
FT                                ECO:0000244|PDB:2YY2,
FT                                ECO:0000244|PDB:3DYN,
FT                                ECO:0000244|PDB:3JSI,
FT                                ECO:0000244|PDB:3JSW,
FT                                ECO:0000244|PDB:3K3E,
FT                                ECO:0000244|PDB:3K3H,
FT                                ECO:0000244|PDB:3N3Z,
FT                                ECO:0000244|PDB:4E90,
FT                                ECO:0000244|PDB:4G2J,
FT                                ECO:0000244|PDB:4G2L,
FT                                ECO:0000244|PDB:4GH6,
FT                                ECO:0000269|PubMed:18757755,
FT                                ECO:0000269|PubMed:19919087,
FT                                ECO:0000269|PubMed:20121115,
FT                                ECO:0000269|PubMed:21483814,
FT                                ECO:0000269|PubMed:22985069,
FT                                ECO:0000269|PubMed:23025719}.
FT   METAL       353    353       Magnesium. {ECO:0000244|PDB:2HD1,
FT                                ECO:0000244|PDB:2YY2,
FT                                ECO:0000244|PDB:3DYN,
FT                                ECO:0000244|PDB:3JSI,
FT                                ECO:0000244|PDB:3JSW,
FT                                ECO:0000244|PDB:3K3E,
FT                                ECO:0000244|PDB:3K3H,
FT                                ECO:0000244|PDB:3N3Z,
FT                                ECO:0000244|PDB:4E90,
FT                                ECO:0000244|PDB:4G2J,
FT                                ECO:0000244|PDB:4G2L,
FT                                ECO:0000244|PDB:4GH6,
FT                                ECO:0000269|PubMed:18757755,
FT                                ECO:0000269|PubMed:19919087,
FT                                ECO:0000269|PubMed:20121115,
FT                                ECO:0000269|PubMed:21483814,
FT                                ECO:0000269|PubMed:22985069,
FT                                ECO:0000269|PubMed:23025719}.
FT   METAL       353    353       Zinc. {ECO:0000244|PDB:2HD1,
FT                                ECO:0000244|PDB:2YY2,
FT                                ECO:0000244|PDB:3DYN,
FT                                ECO:0000244|PDB:3JSI,
FT                                ECO:0000244|PDB:3JSW,
FT                                ECO:0000244|PDB:3K3E,
FT                                ECO:0000244|PDB:3K3H,
FT                                ECO:0000244|PDB:3N3Z,
FT                                ECO:0000244|PDB:4E90,
FT                                ECO:0000244|PDB:4G2J,
FT                                ECO:0000244|PDB:4G2L,
FT                                ECO:0000244|PDB:4GH6,
FT                                ECO:0000269|PubMed:18757755,
FT                                ECO:0000269|PubMed:19919087,
FT                                ECO:0000269|PubMed:20121115,
FT                                ECO:0000269|PubMed:21483814,
FT                                ECO:0000269|PubMed:22985069,
FT                                ECO:0000269|PubMed:23025719}.
FT   METAL       462    462       Zinc. {ECO:0000244|PDB:2HD1,
FT                                ECO:0000244|PDB:2YY2,
FT                                ECO:0000244|PDB:3DYN,
FT                                ECO:0000244|PDB:3JSI,
FT                                ECO:0000244|PDB:3JSW,
FT                                ECO:0000244|PDB:3K3E,
FT                                ECO:0000244|PDB:3K3H,
FT                                ECO:0000244|PDB:3N3Z,
FT                                ECO:0000244|PDB:4E90,
FT                                ECO:0000244|PDB:4G2J,
FT                                ECO:0000244|PDB:4G2L,
FT                                ECO:0000244|PDB:4GH6,
FT                                ECO:0000269|PubMed:18757755,
FT                                ECO:0000269|PubMed:19919087,
FT                                ECO:0000269|PubMed:20121115,
FT                                ECO:0000269|PubMed:21483814,
FT                                ECO:0000269|PubMed:22985069,
FT                                ECO:0000269|PubMed:23025719}.
FT   BINDING     353    353       cGMP. {ECO:0000269|PubMed:18757755}.
FT   BINDING     462    462       cGMP. {ECO:0000269|PubMed:18757755}.
FT   BINDING     484    484       cGMP. {ECO:0000269|PubMed:18757755}.
FT   BINDING     484    484       Inhibitor specific to PDE9A.
FT                                {ECO:0000269|PubMed:21483814,
FT                                ECO:0000269|PubMed:22985069,
FT                                ECO:0000269|PubMed:23025719}.
FT   BINDING     513    513       Inhibitor. {ECO:0000269|PubMed:19919087,
FT                                ECO:0000269|PubMed:20121115,
FT                                ECO:0000269|PubMed:21483814,
FT                                ECO:0000269|PubMed:22985069,
FT                                ECO:0000269|PubMed:23025719}.
FT   VAR_SEQ       1    217       Missing (in isoform PDE9A11).
FT                                {ECO:0000303|PubMed:12565835}.
FT                                /FTId=VSP_017302.
FT   VAR_SEQ       1    207       Missing (in isoform PDE9A7).
FT                                {ECO:0000303|PubMed:12565835}.
FT                                /FTId=VSP_017303.
FT   VAR_SEQ       1    160       Missing (in isoform PDE9A10).
FT                                {ECO:0000303|PubMed:12565835}.
FT                                /FTId=VSP_017304.
FT   VAR_SEQ       1     73       MGSGSSSYRPKAIYLDIDGRIQKVIFSKYCNSSDIMDLFCI
FT                                ATGLPRNTTISLLTTDDAMVSIDPTMPANSER -> MSSFS
FT                                IHHSVTCCFYLVRSHGRPTS (in isoform
FT                                PDE9A21). {ECO:0000303|PubMed:17090334}.
FT                                /FTId=VSP_038647.
FT   VAR_SEQ       1     73       MGSGSSSYRPKAIYLDIDGRIQKVIFSKYCNSSDIMDLFCI
FT                                ATGLPRNTTISLLTTDDAMVSIDPTMPANSER -> MDAFR
FT                                S (in isoform PDE9A3 and isoform
FT                                PDE9A16). {ECO:0000303|PubMed:12565835,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:9856478}.
FT                                /FTId=VSP_004598.
FT   VAR_SEQ       1     46       MGSGSSSYRPKAIYLDIDGRIQKVIFSKYCNSSDIMDLFCI
FT                                ATGLP -> MDAFR (in isoform PDE9A6,
FT                                isoform PDE9A12 and isoform PDE9A17).
FT                                {ECO:0000303|PubMed:12565835,
FT                                ECO:0000303|PubMed:14527714}.
FT                                /FTId=VSP_017305.
FT   VAR_SEQ      24    165       VIFSKYCNSSDIMDLFCIATGLPRNTTISLLTTDDAMVSID
FT                                PTMPANSERTPYKVRPVAIKQLSAGVEDKRTTSRGQSAERP
FT                                LRDRRVVGLEQPRREGAFESGQVEPRPREPQGCYQEGQRIP
FT                                PEREELIQSVLAQVAEQFS -> EHDHLPADHRRRHGLHRP
FT                                HHAREFRTHSVQSETCGHQATL (in isoform
FT                                PDE9A13). {ECO:0000303|PubMed:12565835}.
FT                                /FTId=VSP_017306.
FT   VAR_SEQ      24    165       VIFSKYCNSSDIMDLFCIATGLPRNTTISLLTTDDAMVSID
FT                                PTMPANSERTPYKVRPVAIKQLSAGVEDKRTTSRGQSAERP
FT                                LRDRRVVGLEQPRREGAFESGQVEPRPREPQGCYQEGQRIP
FT                                PEREELIQSVLAQVAEQFS -> HSVQSETCGHQATL (in
FT                                isoform PDE9A4).
FT                                {ECO:0000303|PubMed:9856478}.
FT                                /FTId=VSP_004600.
FT   VAR_SEQ      48     73       Missing (in isoform PDE9A9 and isoform
FT                                PDE9A18). {ECO:0000303|PubMed:12565835}.
FT                                /FTId=VSP_017307.
FT   VAR_SEQ      73    165       Missing (in isoform PDE9A12).
FT                                {ECO:0000303|PubMed:12565835}.
FT                                /FTId=VSP_017308.
FT   VAR_SEQ      74    165       TPYKVRPVAIKQLSAGVEDKRTTSRGQSAERPLRDRRVVGL
FT                                EQPRREGAFESGQVEPRPREPQGCYQEGQRIPPEREELIQS
FT                                VLAQVAEQFS -> NELILYTSLRNLLFLPSKESWASHQHS
FT                                VQSETCGHQATL (in isoform PDE9A5).
FT                                {ECO:0000303|PubMed:12565835}.
FT                                /FTId=VSP_017309.
FT   VAR_SEQ      88    147       Missing (in isoform PDE9A2, isoform
FT                                PDE9A3, isoform PDE9A6, isoform PDE9A9
FT                                and isoform PDE9A21).
FT                                {ECO:0000303|PubMed:12565835,
FT                                ECO:0000303|PubMed:14527714,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17090334,
FT                                ECO:0000303|PubMed:9856478,
FT                                ECO:0000303|Ref.7}.
FT                                /FTId=VSP_004599.
FT   VAR_SEQ     161    165       AEQFS -> MDAFR (in isoform PDE9A10).
FT                                {ECO:0000303|PubMed:12565835}.
FT                                /FTId=VSP_017310.
FT   VAR_SEQ     218    218       R -> M (in isoform PDE9A11).
FT                                {ECO:0000303|PubMed:12565835}.
FT                                /FTId=VSP_017311.
FT   MUTAGEN     312    312       H->A: Completely abolishes catalytic
FT                                activity. {ECO:0000269|PubMed:18757755}.
FT   MUTAGEN     356    356       H->A: Reduces catalytic activity, but has
FT                                no effect on substrate affinity.
FT                                {ECO:0000269|PubMed:18757755}.
FT   MUTAGEN     425    425       M->A: Induces a 2 fold change in
FT                                inhibitory sensivity by BAY-73-9961.
FT                                {ECO:0000269|PubMed:20121115}.
FT   MUTAGEN     463    463       I->A: Induces a 6-9 fold change in
FT                                inhibitory sensivity by BAY-73-9961.
FT                                {ECO:0000269|PubMed:20121115}.
FT   MUTAGEN     466    466       E->A: Decreased affinity and catalytic
FT                                activity for cGMP and cAMP.
FT                                {ECO:0000269|PubMed:21483814}.
FT   MUTAGEN     480    480       L->A: Induces a 6-9 fold change in
FT                                inhibitory sensivity by BAY-73-9961.
FT                                {ECO:0000269|PubMed:20121115}.
FT   MUTAGEN     484    484       Y->A: Induces a 6-9 fold change in
FT                                inhibitory sensivity by BAY-73-9961.
FT                                {ECO:0000269|PubMed:20121115}.
FT   MUTAGEN     501    501       F->A: Induces a 2 fold change in
FT                                inhibitory sensivity by BAY-73-9961.
FT                                {ECO:0000269|PubMed:20121115}.
FT   MUTAGEN     513    513       Q->A: Induces a dramatic change in
FT                                inhibitory sensivity by BAY-73-9961.
FT                                {ECO:0000269|PubMed:20121115}.
FT   MUTAGEN     513    513       Q->E: 2 fold decreased affinity and
FT                                catalytic activity for cGMP. 8 fold
FT                                decreased catalytic activity for cAMP
FT                                without affecting the affinity for cAMP.
FT                                {ECO:0000269|PubMed:21483814}.
FT   MUTAGEN     516    516       F->A: Induces a dramatic change in
FT                                inhibitory sensivity by BAY-73-9961.
FT                                {ECO:0000269|PubMed:20121115}.
FT   CONFLICT     79     79       R -> G (in Ref. 6; BAG57446).
FT                                {ECO:0000305}.
FT   HELIX       250    255       {ECO:0000244|PDB:3DYN}.
FT   HELIX       263    265       {ECO:0000244|PDB:3DYN}.
FT   HELIX       268    281       {ECO:0000244|PDB:3DYN}.
FT   HELIX       284    288       {ECO:0000244|PDB:3DYN}.
FT   HELIX       292    305       {ECO:0000244|PDB:3DYN}.
FT   STRAND      310    313       {ECO:0000244|PDB:3DYN}.
FT   HELIX       314    330       {ECO:0000244|PDB:3DYN}.
FT   HELIX       333    336       {ECO:0000244|PDB:3DYN}.
FT   HELIX       339    351       {ECO:0000244|PDB:3DYN}.
FT   TURN        352    355       {ECO:0000244|PDB:3DYN}.
FT   HELIX       361    367       {ECO:0000244|PDB:3DYN}.
FT   HELIX       370    375       {ECO:0000244|PDB:3DYN}.
FT   HELIX       380    393       {ECO:0000244|PDB:3DYN}.
FT   HELIX       396    398       {ECO:0000244|PDB:3DYN}.
FT   TURN        400    403       {ECO:0000244|PDB:3DYN}.
FT   HELIX       406    422       {ECO:0000244|PDB:3DYN}.
FT   HELIX       425    427       {ECO:0000244|PDB:3DYN}.
FT   HELIX       428    439       {ECO:0000244|PDB:3DYN}.
FT   HELIX       447    462       {ECO:0000244|PDB:3DYN}.
FT   HELIX       465    467       {ECO:0000244|PDB:3DYN}.
FT   HELIX       470    494       {ECO:0000244|PDB:3DYN}.
FT   HELIX       500    502       {ECO:0000244|PDB:3DYN}.
FT   TURN        504    506       {ECO:0000244|PDB:3DYN}.
FT   HELIX       509    519       {ECO:0000244|PDB:3DYN}.
FT   HELIX       521    531       {ECO:0000244|PDB:3DYN}.
FT   HELIX       535    561       {ECO:0000244|PDB:3DYN}.
FT   STRAND      562    564       {ECO:0000244|PDB:4GH6}.
SQ   SEQUENCE   593 AA;  68493 MW;  E2731C7C828C0994 CRC64;
     MGSGSSSYRP KAIYLDIDGR IQKVIFSKYC NSSDIMDLFC IATGLPRNTT ISLLTTDDAM
     VSIDPTMPAN SERTPYKVRP VAIKQLSAGV EDKRTTSRGQ SAERPLRDRR VVGLEQPRRE
     GAFESGQVEP RPREPQGCYQ EGQRIPPERE ELIQSVLAQV AEQFSRAFKI NELKAEVANH
     LAVLEKRVEL EGLKVVEIEK CKSDIKKMRE ELAARSSRTN CPCKYSFLDN HKKLTPRRDV
     PTYPKYLLSP ETIEALRKPT FDVWLWEPNE MLSCLEHMYH DLGLVRDFSI NPVTLRRWLF
     CVHDNYRNNP FHNFRHCFCV AQMMYSMVWL CSLQEKFSQT DILILMTAAI CHDLDHPGYN
     NTYQINARTE LAVRYNDISP LENHHCAVAF QILAEPECNI FSNIPPDGFK QIRQGMITLI
     LATDMARHAE IMDSFKEKME NFDYSNEEHM TLLKMILIKC CDISNEVRPM EVAEPWVDCL
     LEEYFMQSDR EKSEGLPVAP FMDRDKVTKA TAQIGFIKFV LIPMFETVTK LFPMVEEIML
     QPLWESRDRY EELKRIDDAM KELQKKTDSL TSGATEKSRE RSRDVKNSEG DCA
//
